StockData
COSCIENS Biopharma Inc. logo

COSCIENS Biopharma Inc. (CSCIF) stock

CSCIFOTCPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 20-F on Mar 25, 2026Score 1/30
$6.49+0.00 (0.00%)

Close on Oct 19, 2026Market cap $24.10MP/E –Yield –

COSCIENS Biopharma r&d expenses

Research and development expenses are spending on new products and technology.

COSCIENS Biopharma's R&D Expenses for the twelve months ending Mar 31, 2026 was $1.99M, down 74.3% year over year. For fiscal 2025 it was $2.95M, down 64.5% from the year before. Over ten years it grew -16.2% a year on average. The highest annual figure on record is $17.23M in fiscal 2015.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.95M-64.5%
FY2024Dec 31, 2024$8.30M+307.1%
FY2023Dec 31, 2023$2.04M+48.8%
FY2022Dec 31, 2022$1.37M-79.1%
FY2021Dec 31, 2021$6.57M+336.5%
FY2020Dec 31, 2020$1.51M-18.0%
FY2019Dec 31, 2019$1.84M-37.3%
FY2018Dec 31, 2018$2.93M-72.6%
FY2017Dec 31, 2017$10.70M-35.1%
FY2016Dec 31, 2016$16.50M-4.3%
FY2015Dec 31, 2015$17.23M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026$176.00K-64.6%
Q4 FY2025Dec 31, 2025$599.00K-79.4%
Q3 FY2025Sep 30, 2025$527.00K-81.2%
Q2 FY2025Jun 30, 2025$690.00K-54.9%
Q1 FY2025Mar 31, 2025$497.00K-53.2%
Q4 FY2024Dec 31, 2024$2.91M+495.7%
Q3 FY2024Sep 30, 2024$2.80M+542.0%
Q2 FY2024Jun 30, 2024$1.53M+121.4%
Q1 FY2024Mar 31, 2024$1.06M-73.5%
Q4 FY2023Dec 31, 2023$489.00K-88.9%
Q3 FY2023Sep 30, 2023$436.00K-86.8%
Q2 FY2023Jun 30, 2023$691.00K-71.2%
Q1 FY2023Mar 31, 2023$4.01M+67.9%
Q4 FY2022Dec 31, 2022$4.43M+137.5%
Q3 FY2022Sep 30, 2022$3.29M+121.8%
Q2 FY2022Jun 30, 2022$2.40M+35.6%
Q1 FY2022Mar 31, 2022$2.39M+63.9%
Q4 FY2021Dec 31, 2021$1.86M+197.6%
Q3 FY2021Sep 30, 2021$1.49M+299.2%
Q2 FY2021Jun 30, 2021$1.77M+835.4%
Q1 FY2021Mar 31, 2021$1.46M+357.1%
Q4 FY2020Dec 31, 2020$626.00K+138.0%
Q3 FY2020Sep 30, 2020$372.00K-21.7%
Q2 FY2020Jun 30, 2020$189.00K-66.9%
Q1 FY2020Mar 31, 2020$319.00K-39.6%
Q4 FY2019Dec 31, 2019$263.00K-65.7%
Q3 FY2019Sep 30, 2019$475.00K+32.7%
Q2 FY2019Jun 30, 2019$571.00K-41.4%
Q1 FY2019Mar 31, 2019$528.00K–
Q4 FY2018Dec 31, 2018$767.00K–
Q3 FY2018Sep 30, 2018$358.00K–
Q2 FY2018Jun 30, 2018$974.00K–

More COSCIENS Biopharma figures

See a number that looks wrong?